An Open-Label, Multicenter, Phase 1/2 Trial of GEN3014 (HexaBody®-CD38) in Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies.

  • Spencer, Andrew (Primary Chief Investigator (PCI))
  • Kennedy, Nola (Project Manager)
  • Ho, Phoebe Joy (Chief Investigator (CI))
  • Cochrane, Tara (Chief Investigator (CI))
  • Cooke, Rachel E. (Chief Investigator (CI))

Project: Research

Project Details

Project Description

Effective start/end date13/01/2231/12/27


  • Malignant Haematology
  • Multiple myeloma
  • Clinical trial